Home » Stocks » AXNX

Axonics Modulation Technologies, Inc. (AXNX)

Stock Price: $68.38 USD 1.54 (2.30%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 3.06B
Revenue (ttm) 119.61M
Net Income (ttm) -62.80M
Shares Out 39.61M
EPS (ttm) -1.63
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $68.38
Previous Close $66.84
Change ($) 1.54
Change (%) 2.30%
Day's Open 66.55
Day's Range 66.55 - 68.66
Day's Volume 311,244
52-Week Range 34.00 - 68.66

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

2 weeks ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

3 weeks ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

1 month ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

2 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

2 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), (“Axonics”), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bow...

2 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX) (“Axonics”), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and b...

2 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

2 months ago - Business Wire

Axonics (AXNX) delivered earnings and revenue surprises of -12.20% and 23.40%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunctio...

2 months ago - Business Wire

Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunc...

3 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of bladder and bowel dysfunc...

3 months ago - Business Wire

When the market is expensive and overbought like the current one is, it is very important to stay with companies that not only have solid earnings potential but also have upcoming catalysts that can hel...

Other stocks mentioned: BDX, DXCM, MDT
4 months ago - 24/7 Wall Street

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of b...

4 months ago - Business Wire

LISLE, Ill., March 2, 2021 /PRNewswire/ -- Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure (HF), today announced the appointment o...

4 months ago - PRNewsWire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a global medical technology company that has developed and is commercializing novel products for the treatment of b...

4 months ago - Business Wire

Axonics Modulation Technologies Inc (NASDAQ: AXNX) has acquired UK-based Contura and its lead product Bulkamid, a urethral bulking agent used to treat female stress urinary incontinence. The transaction...

5 months ago - Benzinga

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

5 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

5 months ago - Business Wire

On Thursday, February 25, Axonics Modulation Tech (NASDAQ:AXNX) will release its latest earnings report. Benzinga's outlook for Axonics Modulation Tech is included in the following report.

5 months ago - Benzinga

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

5 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

5 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

5 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

5 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

6 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

7 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

8 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

8 months ago - Business Wire

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q3 2020 Results - Earnings Call Transcript

8 months ago - Seeking Alpha

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen On Q3 2020 Results - Quick Earnings Call Transcript

8 months ago - Seeking Alpha

Axonics (AXNX) delivered earnings and revenue surprises of 53.85% and 60.15%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

8 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

9 months ago - Business Wire

Axonics (AXNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

9 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

9 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation dev...

9 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

9 months ago - Business Wire

Axonics (AXNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

9 months ago - Zacks Investment Research

Down Session Has Bullish Undertones

YouTube video

Stock indexes didn’t give up much ground Tuesday after strong gains Monday.

Other stocks mentioned: BYND, ENTG
10 months ago - Investors Business Daily

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SN...

10 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation dev...

10 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

10 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

10 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

10 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

10 months ago - Business Wire

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

10 months ago - Business Wire

Axonics Modulation Technologies, Inc. (AXNX) CEO Raymond Cohen on Q2 2020 Results - Earnings Call Transcript

11 months ago - Seeking Alpha

IRVINE, Calif.--(BUSINESS WIRE)--Axonics Modulation Technologies, Inc.

11 months ago - Business Wire

About AXNX

Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and ... [Read more...]

Industry
Medical Devices
CEO
Raymond Cohen
Employees
416
Stock Exchange
NASDAQ
Ticker Symbol
AXNX
Full Company Profile

Financial Performance

In 2020, AXNX's revenue was $111.54 million, an increase of 707.05% compared to the previous year's $13.82 million. Losses were -$54.92 million, -31.30% less than in 2019.

Financial Statements

Analyst Forecasts

According to 9 analysts, the average rating for AXNX stock is "Strong Buy." The 12-month stock price forecast is 72.20, which is an increase of 5.59% from the latest price.

Price Target
$72.20
(5.59% upside)
Analyst Consensus: Strong Buy